Smaller shot, same effect? study tests concentrated ABP 501

NCT ID NCT05909852

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a more concentrated version of ABP 501 (a biosimilar to the drug adalimumab) works the same in the body as the standard version. 372 healthy adults received a single injection of either the high-concentration or low-concentration form. Researchers measured drug levels in the blood to see if they were comparable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ABP 501 (a biosimilar to adalimumab)

What this could lead to

If successful, this could confirm that a more concentrated version of ABP 501 works just as well as the current one, potentially allowing for smaller injections.

What could go wrong

This is an early-phase study in healthy volunteers, not patients. It only measures drug levels in the blood, not actual treatment effects or safety in people with diseases.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADALIMUMAB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pharmaceutical Research Associates, Inc

    Salt Lake City, Utah, 84124, United States

  • Qps-Mra, Llc

    South Miami, Florida, 33143, United States

  • WCCT Global, Inc

    Cypress, California, 90630, United States